World Library  
Flag as Inappropriate
Email this Article

Lobular carcinoma in situ

Article Id: WHEBN0018403722
Reproduction Date:

Title: Lobular carcinoma in situ  
Author: World Heritage Encyclopedia
Language: English
Subject: Breast cancer, Medullary carcinoma of the breast, Invasive lobular carcinoma, Nipple adenoma, Ductal, lobular, and medullary neoplasms
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Lobular carcinoma in situ

Lobular carcinoma in situ
Classification and external resources
Diagram showing localized and invasive LCIS
ICD-10 D05.0
ICD-O: M8520/2

Lobular carcinoma in situ (LCIS) is a condition caused by unusual cells in the lobules of the breast.[1]

Many do not considered it cancer, but it can indicate an increased risk of future cancer.[2][3][4] The national database registrars, however, consider it a malignancy.[5]

Unlike ductal carcinoma in situ (DCIS), LCIS is not associated with calcification, and is typically an incidental finding in a biopsy performed for another reason. LCIS only accounts for about 15% of the in situ (ductal or lobular) breast cancers.[6]

Genetics

Cells of LCIS and invasive lobular carcinoma have the same histology, appearing as single detached cells, as both have loss of expression of e-cadherin, the transmembrane protein mediating epithelial cell adhesion.[7] LCIS often have the same genetic alterations (such as loss of heterozygosity on chromosome 16q, the locus for the e-cadherin gene) as the adjacent area of invasive carcinoma.[8]

Morphology

Lobular carcinoma in situ, H&E, 20x

Like the cells of atypical lobular hyperplasia and invasive lobular carcinoma, the abnormal cells of LCIS consist of small cells with oval or round nuclei and small nucleoli detached from each other.[9] Mucin-containing signet-ring cells are commonly seen. LCIS generally leaves the underlying architecture intact and recognisable as lobules. Estrogen and progesterone receptors are present and HER2/neu overexpression is absent in most cases of LCIS.[9]

Treatment options

LCIS may be treated with close clinical follow-up and mammographic screening, tamoxifen or related hormone controlling drugs to reduce the risk of developing cancer, or bilateral prophylactic mastectomy. Some surgeons consider bilateral prophylactic mastectomy to be overly aggressive treatment except for certain high-risk cases.[10]

Prognosis

LCIS (lobular neoplasia is considered pre-cancerous) is an indicator (marker) identifying women with an increased risk of developing invasive breast cancer. This risk extends more than 20 years. Most of the risk relates to subsequent invasive ductal carcinoma rather than to invasive lobular carcinoma.[10]

While older studies have shown that the increased risk is equal for both breasts, a more recent study suggests that the ipsilateral (same side) breast may be at greater risk.[11]

See also

References

  1. ^ "Lobular Carcinoma in situ (LCIS)". Breast Cancer. Stanford Cancer Center. 
  2. ^ "Lobular carcinoma in situ: Marker for breast cancer risk". MayoClinic.com. 
  3. ^ "Breast Cancer Treatment". National Cancer Institute. 
  4. ^ Afonso N, Bouwman D (August 2008). "Lobular carcinoma in situ". Eur. J. Cancer Prev. 17 (4): 312–6.  
  5. ^ Cancer, American Joint Committee on (2002). AJCC cancer staging handbook : from the AJCC cancer staging manual (6th ed. ed.). New York: Springer. p. 260.  
  6. ^ "Susan G. Komen for the Cure | Understanding Breast Cancer | Breast Facts | Statistics | Breast Cancer Statistics". Retrieved 2013-01-16. 
  7. ^ Hajra KM, Fearon ER (2002). "Cadherin and catenin alterations in human cancer". Genes Chromosomes Cancer 34 (3): 255–68.  
  8. ^ Lakhani SR (2001). "Molecular genetics of solid tumors: translating research into clinical practice. What we could do now: breast cancer". Mol Pathol 54 (5): 281–4.  
  9. ^ a b Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, MO: Elsevier Saunders. p. 1142.  
  10. ^ a b "In Situ"Breast Cancer Treatment (PDQ®) - National Cancer Institute - Lobular Carcinoma . Retrieved 2013-01-12. 
  11. ^ Page DL, Schuyler PA, DuPont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003). "Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study". Lancet 361 (9352): 125–9.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.